SEQUOIAHCM: Effect of aficamten treatment on patients with hypertrophic obstructive cardiomyopathy by geographical region

18 May 2025 (11:11 - 11:19)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Caroline Coats

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

20 More presentations in this session

Presentation thumbnail

DIGITHF: Baseline characteristics compared to recent trials in heart failure with reduced ejection fraction

Professor U. Bavendiek (Hannover, DE)

Presentation thumbnail

Discussant review - DIGITHF

Professor D. van Veldhuisen (Groningen, NL)

Presentation thumbnail

Panel discussion - DIGITHF

Presentation thumbnail

CIRRUSHCM: A multiple-dose phase 2 study of safety, tolerability, and effects on hemodynamics and functional capacity of the novel cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy

Doctor A. Owens (Philadelphia, US)

Presentation thumbnail

Discussant review - CIRRUSHCM

Professor I. Olivotto (Florence, IT)

Access the full session

Session thumbnail

Hottest trials and trial updates (2)

The Event

Event poster

Heart Failure 2025

18 May 2025 11:11 CET

You may be interested in

Congress Presentation

Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial

Congress Presentation

Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM

Congress Presentation

Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources